The promise of apolipoprotein AI mimetics
AJ Mendez - Current Opinion in Endocrinology, Diabetes and …, 2010 - journals.lww.com
Current Opinion in Endocrinology, Diabetes and Obesity, 2010•journals.lww.com
Clinical trials of relatively short-term synthetic HDL infusion into patients with CHD
demonstrate beneficial effects. Use of apo AI mimetic peptides could potentially overcome
some of the limitations associated with use of the intact apo. Studies to establish the most
efficacious peptides, optimal dosing regimens, and routes of administration are needed. Use
of apo AI mimetic peptides shows great promise as a therapeutic modality for HDL
replacement and enhancing HDL function in treatment of patients with CHD.
demonstrate beneficial effects. Use of apo AI mimetic peptides could potentially overcome
some of the limitations associated with use of the intact apo. Studies to establish the most
efficacious peptides, optimal dosing regimens, and routes of administration are needed. Use
of apo AI mimetic peptides shows great promise as a therapeutic modality for HDL
replacement and enhancing HDL function in treatment of patients with CHD.
Summary
Clinical trials of relatively short-term synthetic HDL infusion into patients with CHD demonstrate beneficial effects. Use of apo AI mimetic peptides could potentially overcome some of the limitations associated with use of the intact apo. Studies to establish the most efficacious peptides, optimal dosing regimens, and routes of administration are needed. Use of apo AI mimetic peptides shows great promise as a therapeutic modality for HDL replacement and enhancing HDL function in treatment of patients with CHD.
Lippincott Williams & Wilkins